Antimicrobial Susceptibility Among Gram-Negative Isolates Collected From Intensive Care Units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa Between 2004 and 2009 as Part of the Tigecycline Evaluation and Surveillance Trial

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages 124-137

  Bertrand, Xavier ^a   Dowzicky, Michael J ^b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial; Gram negative bacteria; ICU; Resistance; Surveillance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ADULT; AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOGEOGRAPHIC REGION; DRUG SCREENING; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EUROPE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NORTH AMERICA; PRACTICE GUIDELINE; SERRATIA MARCESCENS; SOUTH AND CENTRAL AMERICA;

ADOLESCENT; ADULT; AFRICA; AGED; ANTI-INFECTIVE AGENTS; ASIA; DRUG RESISTANCE, BACTERIAL; EUROPE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LATIN AMERICA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MIDDLE EAST; MINOCYCLINE; NORTH AMERICA; TIME FACTORS; YOUNG ADULT;

EID: 84856139754     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.11.023     Document Type: Article

References (22)

1. Livermore D.M. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64(Suppl 1):i29-i36.
2. Falagas M.E., Karageorgopoulos D.E. Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 2009, 73:345-354.
3. Fishbain J., Peleg A. Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51:79-84.
4. Shorr A.F. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009, 37:1463-1469.
5. Low D.E., Markovic M.J., Dowzicky M.J. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the Tigecycline Evaluation and Surveillance Trial in North America. J Chemother 2009, 21:16-23.
6. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 2009, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, Penn. 8th ed.
7. Performance Standards for Antimicrobial Susceptibility Testing 2010, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, Penn. 20th ed.
8. Performance Standards for Antimicrobial Susceptibility Testing 2010, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, Penn. 20th ed.
9. Tygacil Product Insert Pfizer Inc (Wyeth Pharmaceuticals), Philadelphia, Pennsylvania. Last Revised January 2011, Accessed February 16, 2011. http://www.pfizerpro.com/hcp/tygacil.
10. Moet G.J., Jones R.N., Biedenbach D.J., et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY antimicrobial surveillance program (1998-2004). Diagn Microbiol Infect Dis 2007, 57:7-13.
11. Rossi F., Baquero F., Hsueh P.-R., et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolates from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006, 58:205-210.
12. Farrell D.J., Turnidge J.D., Bell J., et al. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 2010, 60:440-451.
13. Yang Q., Wang H., Chen M., et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2010, 36:507-512.
14. Sader H.S., Farrell D.J., Jones R.N. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn Microbiol Infect Dis 2011, 69:223-227.
15. Bishburg E., Bishburg K. Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 2009, 34:395-401.
16. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62:45-55.
17. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63:775-780.
18. Jones R.N., Stilwell M.G., Rhomberg P.R., Sader H.S. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn Microbiol Infect Dis 2009, 65:331-334.
19. Fluit A.C., Florijn A., Verhoef J., Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005, 49:1636-1638.
20. Lautenbach E., Metlay J.P., Bilker W.B., et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005, 41:923-929.
21. Hsueh P.R., Badal R.E., Hawser S.P., et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010, 36:408-414.
22. Mendes R.E., Farrell D.J., Sader H.S., Jones R.N. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn Microbiol Infect Dis 2010, 68:307-311.